Age-dependent decline in renal function in patients with lung cancer

Abstract

Abstract. The aim of this study was to clarify the effect of aging on renal function. Serum creatinine (SCr), blood urea nitrogen (BUN) and 24-h creatinine clearance (measuredCrCl) were examined in lung cancer patients and the measured-CrCl were compared with CrCl estimates by employing two commonly used equations. In total, 787 lung cancer patients who were diagnosed between 2001 and 2010 were retrospectively analyzed. SCr and urine creatinine, BUN and measured-CrCl were evaluated prior to treatment. The Cockcroft-Gault (CG) and modification of diet in renal disease (MDRD) formulae were also used to estimate CrCl. SCr, BUN and measured-CrCl showed a significant decline in the elderly. In the 787 lung cancer patients, a significant correlation coefficient was found between measured-CrCl and age. However, in patients aged 80 years or older, no significant correlation coefficient was found between measured-CrCl and age. In the comparison between the measured CrCl and the CrCls estimated by the two formulae, the CG-CrCl levels were lower than those of the measured-CrCl, whereas the MDRDCrCl levels were higher. Age is a crucial factor influencing renal function in patients with lung cancer. Particularly in the elderly, a decline in CrCl and greater individual variability in CrCl, as well as discrepancies in measured-CrCl and estimated CrCls are significant factors.

A Pilot Study of Prediction of Creatinine Clearance by Ellipsoid Volumetry of Kidney Using Noncontrast Computed Tomography

“…As shown in Table 1 , eCCr was significantly lower than mCCr, suggesting that eCCr predicted by the Cockcroft–Gault equation tends to be underestimated. This tendency was also reported by Ohara et al (29) , who surveyed 787 patients (80% male) with lung cancer at a median age of 70 years. Notably, the difference between mCCr and eCCr in the present study was greater in female patients ( Table 1 ).…”

Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Renal Impairment

“…5 A recent study demonstrated an age-dependent decline in renal function in patients with lung cancer and greater individual variability in creatinine clearance (CrCl) as well as discrepancies in measured CrCl and estimated CrCl among elderly patients with lung cancer. 6 Cisplatin, commonly used with gemcitabine, docetaxel, or pemetrexed as part of chemotherapy doublets in the management of nonesmall-cell lung cancer (NSCLC), has been associated with dose-limiting nephrotoxicity that manifests as acute renal failure, hypokalemia, hypomagnesaemia, or Fanconi-like syndrome. 7 Carboplatin is considered to be substantially less nephrotoxic than cisplatin; however, proper dosing relies on renal function, 8 and its pharmacokinetic profile has not been well established at lower levels of renal function.…”

A database for lung cancer prediction models - a Danish cohort study of nearly 40,000 patients

“…Low albumin indicates malnutrition and has been associated with poor survival in several cancer types [50]. Differences in creatinine levels might be confounded by a higher age of the LC cohort since s-creatinine levels decrease with increasing age [51]. Thrombocytopenia is not commonly seen among LC patients, whereas a recent literature review shows thrombocytosis to be generic across all sub-types of LC [52].…”